Concepedia

Oleksandr Sverdlov

OS

Statistics

Publications

28

Citations

991

H-Index

18

Active since

2008

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

University of California, Los Angeles

Uppsala University

Bristol-Myers Squibb (United States)

Oleksandr Sverdlov is an author at Novartis (United States) specializing in biostatistics, randomized controlled trials, and experimental design.

ORCID

Publications per year

2008–2024

28

Publications

28

Handling Covariates in the Design of Clinical Trials

William F. Rosenberger, Oleksandr Sverdlov · Statistical Science · 2008 · 182 citations · Full text

, , +13

A roadmap to using randomization in clinical trials

Vance W. Berger, Louis Bour, Kerstine Carter et al. · BMC Medical Research Methodology · 2021 · 128 citations · Full text

, , +16

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers

Gary Tong, Junsheng Wang, Oleksandr Sverdlov et al. · Clinical Therapeutics · 2012 · 65 citations

, , +6

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

Charles F. Albright, Randy Dockens, Jere E. Meredith et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 63 citations

, , +17

A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects

Randy Dockens, Junsheng Wang, Lorna Castaneda et al. · Clinical Pharmacokinetics · 2012 · 47 citations

, , +8

1–5 of 28